

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Jean-Marc Balloul et al.) Group Art Unit:
Application No.:) Examiner:
Filed: July 2, 2004) Confirmation No.:
For: COMBINATION PRODUCTS USEABLE)
FOR AN ANTI-TUMOR TREATMENT)
(AS AMENDED))

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Date July 2, 2004

By: 

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Complete Known

Substitute for form 1449A/PTO & 1449B/PTO

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number 10/500709
Filing Date July 2, 2004
First Named Inventor Jean-Marc BALLOUL et al.
Examiner Name
Attorney Docket Number 017753-190

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	01 30381		WO	05-03-2001				*			

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BIRCHENALL Roberts M C et al., "Inhibition of murine monocyte proliferation by a colonystimulating factor-1 antisense oligodeoxynucleotide", Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, Vol 145, No. 10, November 15, 1990, pages 3290-3296, XP002957654, ISSN: 0022-1767.
	AHARINEJAP SEYEDHOSSEIN et al., "Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice", Cancer Research, Vol. 62, No. 18, September 15, 2002, pages 5317-5324, XP002247522, ISSN: 0008-5472.
	WONG et al., Database EMBL "Online!", September 2, 1990, "Human macrophage-specific colony-stimulating factor (CSF-1) mRNA, complete cds", retrieved from EBI, Database accession no. M37435, XP002254237.
	KESHAVA N et al., "Blocking of Colony stimulating factor expression with antisense RNA in breast and ovarian cancer epithelial cells leads to programmed cell death", Proceeding of The Annual Meeting of The American Association For Cancer Research, New York, NY, US, Vol. 38, 1997, Page 500, XP002165344, ISSN: 0197-016X.
	KESHAVA N et al., "Overexpression of macrophage colony-stimulating factor (CSF-1) and its receptor, c-fms, in normal ovarian granulosa cells leads to cell proliferation and tumorigenesis", Journal of The Society For Gynecologic Investigation, US, 1999 Jan-Feb, Vol. 6, No. 1, January 1999, Pages 41-49, XP002254236, ISSN: 1071-5576.
	UHLMANN E et al., "Antisense Oligonucleotides: A New Therapeutic Principle", Chemical Reviews, American Chemical Society, Easton, US, Vol 90, No. 4, June 1, 1990, Pages 543-584, XP000141412, ISSN: 0009-2665.

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.